Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I-IIIA
about
Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.KIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer.Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.Orai3 is a predictive marker of metastasis and survival in resectable lung adenocarcinoma.Impact of in vitro chemosensitivity test-guided platinum-based adjuvant chemotherapy on the surgical outcomes of patients with p-stage IIIA non-small cell lung cancer that underwent complete resection.An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy.Prognostic and predictive biomarkers post curative intent therapy.Molecular mechanisms of pathological tumor transformation and their clinical implications: predictors of pulmonary adenocarcinoma transformation into small cell carcinoma.Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.Standardized Uptake Values Derived from 18F-FDG PET May Predict Lung Cancer Microvessel Density and Expression of KI 67, VEGF, and HIF-1α but Not Expression of Cyclin D1, PCNA, EGFR, PD L1, and p53.Upregulation of HOXA11 during the progression of lung adenocarcinoma detected via multiple approaches
P2860
Q36333164-047EC971-AD24-442B-80A3-E08E7925C58AQ36819651-E32D8C42-4F38-4800-9F28-16DD3873F2ACQ37696112-34342B54-D410-462D-9992-49C811D49DA6Q37697189-54E54A50-45DC-48D8-8D73-C54B1FBABA0AQ38622807-4D58FDE4-71C9-4F6C-B925-FC34D0D3D4E7Q39180729-686FCFDB-2015-4D4A-92AF-5AD2C72BB522Q43026297-FC36772A-199C-489A-8A33-2C58D41BCCE9Q47120303-90C75952-EEB8-492F-83DB-960F629744B9Q55159440-2DEC1AD5-3934-4D15-A908-F037AD05184CQ55492679-F1A69742-969B-4C82-B0AA-F1591FE11E23Q58779335-F9DD89F8-8ECC-4787-929C-3FB480D48B00
P2860
Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I-IIIA
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Biomarkers for efficacy of adj ...... section in NSCLC stages I-IIIA
@ast
Biomarkers for efficacy of adj ...... section in NSCLC stages I-IIIA
@en
Biomarkers for efficacy of adj ...... section in NSCLC stages I-IIIA
@nl
type
label
Biomarkers for efficacy of adj ...... section in NSCLC stages I-IIIA
@ast
Biomarkers for efficacy of adj ...... section in NSCLC stages I-IIIA
@en
Biomarkers for efficacy of adj ...... section in NSCLC stages I-IIIA
@nl
prefLabel
Biomarkers for efficacy of adj ...... section in NSCLC stages I-IIIA
@ast
Biomarkers for efficacy of adj ...... section in NSCLC stages I-IIIA
@en
Biomarkers for efficacy of adj ...... section in NSCLC stages I-IIIA
@nl
P3181
P1476
Biomarkers for efficacy of adj ...... section in NSCLC stages I-IIIA
@en
P2093
J. B. Sorensen
S. Wallerek
P304
P3181
P356
10.1183/16000617.00005814
P407
P577
2015-06-01T00:00:00Z